SOURCE: Equity News Circuit

Equity News Circuit

May 14, 2013 08:15 ET

Free Research Reports on CLWR, DDD, SNE and THRX Issued by the Bedford Report

Note to Editors: The Following Is an Investment Opinion Being Issued by the EQUITY NEWS CIRCUIT

NEW YORK, NY--(Marketwired - May 14, 2013) - The Bedford Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Bedford is an essential resource for hundreds of thousands of investors across the country.

Clearwire Corporation (NASDAQ: CLWR) shares have gained approximately 10.0 percent year-to-date. The company announced that a second shareholder advisory firm, Egan-Jones, has backed Sprint's deal to acquire Clearwire. Shareholders are scheduled to vote on the deal next Tuesday.

Find out more about Clearwire including full access to the free equity report at: www.BedfordReport.com/CLWR

3D Systems Corporation (NYSE: DDD) shares increased roughly 7.3 percent on volume of over 7.0 million shares traded Monday. Canaccord Genuity analyst Bobby Burleson has recently raised his price target on the company to $50.00 from $45.00 shares of 3D Systems have gained over 30 percent in the past month.

Find out more about 3D Systems including full access to the free equity report at: www.BedfordReport.com/DDD

Sony Corporation (NYSE: SNE) shares spiked nearly 6.0 percent on volume of over 5.0 million shares traded Monday. The company introduced its waterproof Xperia ZR Android smartphone, which can be submerged in up to 1.5 meters of fresh water for as long as 30 minutes. Sony has stated that the smartphone has "the highest level of water-resistance for capturing photos and Full HD videos underwater."

Find out more about Sony including full access to the free equity report at: www.BedfordReport.com/SNE

Theravance Inc. (NASDAQ: THRX) shares surged roughly 15.5 percent on volume of over 7.0 million shares traded Monday. The company announced it has entered into a $1.0 billion royalty participation agreement with Elan Corp. Shares of the biotech company have soared over 80 percent year-to-date.

Find out more about Theravance including full access to the free equity report at: www.BedfordReport.com/THRX

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A third party, Providence Media Strategies LLC has paid Equity News Circuit five hundred dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release. Neither Equity News Circuit nor the hiring party are a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security.

Contact Information